文献速递肺结节与肺癌肺栓塞与肺血管病呼吸危重症与机械通气

原发性肺动脉大细胞神经内分泌癌一例并文献复习

[Primary large cell neuroendocrine carcinoma of pulmonary artery: a case report and literature review].
PubMed 文献 · Zhonghua Jie He He Hu Xi Za Zhi · 2026-01-01

本文回顾性分析1例以抗凝无效「肺栓塞」为首发表现的59岁男性原发性肺动脉大细胞神经内分泌癌(LCNEC)患者,经肺动脉内膜剥脱术后确诊,分子病理提示NRAS外显子3复合突变。患者接受EP方案、伊立替康及斯鲁利单抗+安罗替尼+替莫唑胺三线治疗,末次随访总生存期超过33个月。文献复习仅纳入1例相似病例,提示该病极为罕见,根治性手术联合铂类化疗为主要治疗方式。

要点

  • 抗凝无效的「肺栓塞」需警惕肺动脉LCNEC或肺动脉肉瘤等罕见病因。
  • 根治性手术联合铂类化疗是原发性肺动脉LCNEC的主要治疗方式。
  • 分子检测(如NRAS突变)可为个体化治疗提供依据,多线综合治疗可能延长生存。

核心结论

  • 原发性肺动脉LCNEC临床表现缺乏特异性,易误诊为肺栓塞或肺动脉肉瘤,根治性手术联合铂类化疗为主要治疗方式,分子检测可指导个体化治疗,多线综合治疗可能带来生存获益。

研究设计与样本

  • 回顾性分析1例以抗凝无效肺栓塞为首发表现的肺动脉LCNEC患者资料,并行系统性文献复习,检索中外数据库总结临床表现、病理特征、分子标记及治疗进展。

主要发现

  • 患者为59岁男性,经肺动脉内膜剥脱术后确诊为肺动脉LCNEC,分子病理提示NRAS外显子3复合突变。
  • 患者先后接受EP方案、伊立替康、以及斯鲁利单抗+安罗替尼+替莫唑胺三线治疗,截至末次随访总生存期已超过33个月。
  • 文献检索仅纳入1例相似病例,表明该病极为罕见。

临床怎么用

  • 对正规抗凝无效的「肺栓塞」患者应警惕肺动脉LCNEC等罕见病因,必要时行肺动脉内膜剥脱术获取病理确诊。
  • 确诊后以根治性手术联合铂类化疗为主要治疗,并完善分子检测(如NRAS)以指导个体化多线综合治疗。

局限性

  • 本文为单例病例报告并文献复习,文献检索仅纳入1例相似病例,证据级别有限,结论需更多病例积累验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the clinical features, diagnostic approaches, and treatment strategies of primary pulmonary artery large cell neuroendocrine carcinoma (LCNEC), and to improve clinicians' awareness of this rare disease. Methods: A retrospective analysis was conducted on the clinical data of a patient with primary pulmonary artery LCNEC, who initially presented with anticoagulation-refractory "pulmonary embolism." A systematic literature review was also performed by searching domestic and international databases to summarize the clinical presentations, pathological characteristics, molecular markers, and therapeutic advances of this disease. Results: The patient was a 59-year-old male diagnosed with pulmonary artery LCNEC after pulmonary endarterectomy. Molecular pathological analysis identified a compound NRAS exon 3 mutation. The patient subsequently received etoposide plus cisplatin (EP), irinotecan, and third-line combination therapy of serplulimab, anlotinib, and temozolomide. At the last follow-up, overall survival exceeded 33 months. The literature review identified only one similar reported case, highlighting the extreme rarity of this disease. Conclusions: Primary pulmonary artery LCNEC lacks specific clinical manifestations and is easily misdiagnosed as pulmonary embolism or pulmonary artery sarcoma. Radical surgery combined with platinum-based chemotherapy constitutes the mainstay of treatment. Molecular testing can provide a basis for personalized therapy, and multiline comprehensive treatment may offer prolonged survival benefits for patients. 目的: 探讨原发性肺动脉大细胞神经内分泌癌(LCNEC)的临床特征、诊断方法及治疗策略,提高临床对该罕见疾病的认识。 方法: 回顾性分析1例以抗凝无效肺栓塞为首发表现的肺动脉LCNEC患者资料,并行系统性文献复习。检索中外数据库,总结其临床表现、病理特征、分子标记及治疗进展。 结果: 患者为59岁男性,经肺动脉内膜剥脱术后确诊为肺动脉LCNEC,分子病理提示NRAS外显子3复合突变。患者先后接受EP方案、伊立替康、以及斯鲁利单抗+安罗替尼+替莫唑胺三线治疗,截至末次随访总生存期已超过33个月。文献检索仅纳入1例相似病例,表明该病极为罕见。 结论: 原发性肺动脉LCNEC临床表现缺乏特异性,易误诊为肺栓塞或肺动脉肉瘤。根治性手术联合铂类化疗为主要治疗方式。分子检测可为个体化治疗提供依据,多线综合治疗可能为患者带来更长的生存获益。.

来源:Zhonghua Jie He He Hu Xi Za Zhi,查看原文。版权归原作者所有。

引用

  1. Kong YH, Liu F, Wang S, et al. [Primary large cell neuroendocrine carcinoma of pulmonary artery: a case report and literature review]. Zhonghua Jie He He Hu Xi Za Zhi. 2026. PMID: 42236456. doi:10.3760/cma.j.cn112147-20251205-00767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。